Ultimate magazine theme for WordPress.

Royalty Pharma will announce financial results for the second quarter of 2021 on August 11, 2021

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) – Royalty Pharma plc (Nasdaq: RPRX) announced today that it will release its financial results for the second quarter of 2021 on Wednesday, August 11, 2021 ahead of the US financial markets opening . The company will host a conference call and webcast at 8:00 a.m. Eastern time that day.

Conference call information

The conference call can be accessed live over the phone for US callers at (833) 519-1253 or for international callers at +1 (914) 800-3826. The access code for the conference call is 1190246.

A live webcast is available on the Investors page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A recording of the conference call and webcast will be archived on the company’s website for a minimum of 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest biopharmaceutical royalty buyer and leading innovator in the entire biopharmaceutical industry pharmaceutical company. Royalty Pharma has assembled a portfolio of royalties that entitle you to payments based directly on sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it co-finances with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties for more than 45 commercial products, including AbbVie and J & J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, J & J’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta and Vertex’s Kalydeco, Ork Triambi, Symdeko Ork Triambi and nine product candidates in the development phase. More information is available at http://www.royaltypharma.com.

The story goes on

Royalty Pharma investor relations and communications

+1 (212) 883-6772
[email protected]

Comments are closed.